{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae HSV-2 Type Specific IgG",
        "LIAISON\u00ae Control HSV-2 IgG"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K081687",
    "Predicate Device Reference 510(k) Number(s)": [
        "K000238"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MYF",
        "JJX"
    ],
    "Summary Letter Date": "December 4, 2008",
    "Summary Letter Received Date": "October 10, 2008",
    "Submission Date": "October 9, 2008",
    "Regulation Number(s)": [
        "21 CFR 866.3305"
    ],
    "Regulation Name(s)": [
        "Herpes Simplex Virus serological reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "immunology",
        "serology"
    ],
    "Analyte(s)": [
        "HSV-2 IgG"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Indirect immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Chemiluminescence"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON\u00ae HSV-2 Type Specific IgG chemiluminescent immunoassay for detection of HSV-2 IgG in human serum",
    "Indications for Use Summary": "Qualitative determination of HSV-2 type specific IgG antibodies in serum from sexually active adults or expectant mothers to aid presumptive diagnosis of HSV-2 infection; controls monitor assay performance.",
    "fda_folder": "Microbiology"
}